Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat + azacitidine + lipo-MIT for relapsed/refractory peripheral T-cell lymphoma (phase 2, single-arm)
ChiCTR2600116686Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jan 2026
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat, azacitidine and mitoxantrone in peripheral T-cell lymphoma (PTCL), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall response rate after 6 cycles. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
zeprumetostatazacitidinemitoxantrone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR2600116686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116686.